BR112022007635A2 - Formulação aquosa e estável de anticorpos - Google Patents

Formulação aquosa e estável de anticorpos

Info

Publication number
BR112022007635A2
BR112022007635A2 BR112022007635A BR112022007635A BR112022007635A2 BR 112022007635 A2 BR112022007635 A2 BR 112022007635A2 BR 112022007635 A BR112022007635 A BR 112022007635A BR 112022007635 A BR112022007635 A BR 112022007635A BR 112022007635 A2 BR112022007635 A2 BR 112022007635A2
Authority
BR
Brazil
Prior art keywords
aqueous
antibody formulation
formulation
stable antibody
antibody
Prior art date
Application number
BR112022007635A
Other languages
English (en)
Inventor
Joseph Crowley Thomas
Lee Dufield Robert
Juneau Jennifer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112022007635A2 publication Critical patent/BR112022007635A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAÇÃO AQUOSA E ESTÁVEL DE ANTICORPOS. A presente invenção refere-se ao campo das formulações farmacêuticas de anticorpos. Especificamente, a presente invenção refere-se a uma formulação líquida e estável de anticorpos e a sua preparação farmacêutica e uso. Esta invenção é exemplificada por uma formulação aquosa de um anticorpo anti-inibidor da Via do Fator Tecidual (TFPI).
BR112022007635A 2019-11-13 2020-11-10 Formulação aquosa e estável de anticorpos BR112022007635A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934781P 2019-11-13 2019-11-13
US202063081409P 2020-09-22 2020-09-22
PCT/IB2020/060571 WO2021094917A1 (en) 2019-11-13 2020-11-10 Stable aqueous anti-tfpi antibody formulation

Publications (1)

Publication Number Publication Date
BR112022007635A2 true BR112022007635A2 (pt) 2022-07-12

Family

ID=73790141

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007635A BR112022007635A2 (pt) 2019-11-13 2020-11-10 Formulação aquosa e estável de anticorpos

Country Status (11)

Country Link
US (1) US20230035617A1 (pt)
EP (1) EP4058061A1 (pt)
JP (1) JP2021088548A (pt)
KR (1) KR20220100634A (pt)
CN (1) CN114786717A (pt)
AU (1) AU2020385048A1 (pt)
BR (1) BR112022007635A2 (pt)
CA (1) CA3160806A1 (pt)
IL (1) IL292493A (pt)
MX (1) MX2022005836A (pt)
WO (1) WO2021094917A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2562114C2 (ru) * 2008-12-22 2015-09-10 Ново Нордиск А/С Антитела против ингибитора метаболического пути тканевого фактора
JP2013520476A (ja) * 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
WO2011147921A1 (en) * 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
RU2699544C2 (ru) * 2015-01-28 2019-09-06 Пфайзер Инк. Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
KR20230074843A (ko) * 2015-08-19 2023-05-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도

Also Published As

Publication number Publication date
EP4058061A1 (en) 2022-09-21
US20230035617A1 (en) 2023-02-02
CN114786717A (zh) 2022-07-22
CA3160806A1 (en) 2021-05-20
MX2022005836A (es) 2022-06-09
JP2021088548A (ja) 2021-06-10
AU2020385048A1 (en) 2022-06-02
WO2021094917A1 (en) 2021-05-20
KR20220100634A (ko) 2022-07-15
IL292493A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
BR112017014376A2 (pt) formulação aquosa estável de anticorpos antifator de crescimento endotelial vascular (vegf) e uso
WO2019171253A8 (en) Anti-pd-1 antibody compositions
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
WO2021021837A3 (en) Anti-pvrig antibodies formulations and uses thereof
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
EA202192405A1 (ru) Составы антител против il-36r
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
BR112021019959A2 (pt) Anticorpo biespecífico, e, formulação farmacêutica
MA54052A (fr) Formulation d'anticorps
CL2020000700A1 (es) Procedimiento de calibración de una bomba peristáltica, procedimiento de dispensación de una cantidad de líquido mediante una bomba peristáltica y dispositivo para la elaboración de preparaciones estériles que puede ejecutar los mismos
EA201992027A1 (ru) Водный состав антитела против pd-l1
MA48461A (fr) Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
MA54139A (fr) Formulation d'anticorps
CO2020013571A2 (es) Formulaciones estables de anticuerpos terapéuticos
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3946454A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF AN ANTI-IL17A ANTIBODY AND ITS USE
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
BR112022007635A2 (pt) Formulação aquosa e estável de anticorpos
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
BR112018005931A2 (pt) composições de anticorpo para hiv e métodos de uso

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)